GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%.Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 billion.
週三，葛蘭素史克公司（紐交所：GSK）報告第三季度銷售額爲104.2億美元（80.1億英鎊），同比下降2%，按不變貨幣計算增長2%。分析師預計銷售額爲107.8億美元。
Vaccine sales fell 18% (-15% at constant currency) to 2.65 billion pounds.
疫苗銷售額下降18%（按不變貨幣計算下降15%），至26.5億英鎊。
Vaccine sales performance was primarily impacted by lower sales of Arexvy with changes in Advisory Committee on Immunization Practices (ACIP) guidelines, prioritization of COVID-19 vaccinations in the quarter, lower seasonal infections, and a tough comparator following launch stocking last year.
疫苗銷售業績主要受到Arexvy銷售減少、免疫規劃諮詢委員會（ACIP）指南變化、該季度COVID-19疫苗優先接種、季節性感染減少以及相較於去年上市備貨的嚴格比較的影響。
Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%.
Shingrix銷售額達到73900萬英鎊，按不變貨幣計算下降7%，Arexvy銷售額爲18800萬英鎊，下降72%。
Also Read: Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
此外閱讀: 輝瑞爲年輕成人RSV疫苗獲批後，葛蘭素史克發佈鼓舞人心的初步數據，顯示在更廣泛人群中的潛在用途
Specialty Medicine sales increased 14% to 2.97 billion pounds. HIV drug revenues increased by 8% to 1.75 billion pounds.
特殊藥物銷售增長14%，達到29.7億英鎊。艾滋病藥物收入增長8%，達到17.5億英鎊。
General Medicines sales rose by 3% to 2.39 billion pounds. The company added General Medicines, including Trelegy, also continued to perform better than expected.
普通藥物銷售增長3%，達到23.9億英鎊。該公司補充道，包括Trelegy在內的普通藥物表現也持續好於預期。
Trelegy (asthma drug) sales reached 600 million pounds, up 12%
Trelegy（哮喘藥物）銷售額達到60000萬英鎊，增長12%
The company reported core EPS of $1.29 (49.7 pence), up 5% on a constant currency and down 1% on a reported basis, beating the consensus of $1.23.
公司報告了核心每股收益爲1.29美元（49.7便士），按恒定貨幣計算增長了5%，按報告基礎下降了1%，高於1.23美元的共識。
"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, " said Emma Walmsley, CEO.
「專科藥品強勁增長有助於抵消生物-疫苗銷售下降，並反映了腫瘤學和艾滋病領域成功的新產品推出，」首席執行官艾瑪·沃姆斯利表示。
Guidance: GSK reaffirms 2024 adjusted EPS growth of 10%- 12%, with core operating profit increasing by 11%- 13% and sales expanding by 7% %- 9%.
指引：GSK重申2024年調整後每股收益增長爲10%- 12%，核心營業利潤增長爲11%- 13%，銷售增長爲7% %- 9%。
Vaccine sales are expected to decrease in low-single-digit percent compared to earlier guidance of an increase in low to mid-single-digit percent.
生物-疫苗銷售預計將與先前指引的低至中等個位數百分比相比下降。
Specialty Medicine revenue is expected to grow at a high teens percent, compared to a prior growth range of mid-to-high teens percent.
預計專科藥品營收將以高十幾個百分比增長，相比之前的中至高十幾個百分比增長區間。
General Medicines 2024 sales are forecasted to increase at mid-single digit percent compared to earlier guidance of low to mid-single digit percent.
2024年普通藥品銷售預計將以中個位數百分比增長，與先前指引的低至中個位數百分比增長相比。
Price Action: At last check on Wednesday, GSK stock was down 4.69% to $36.38 during the premarket session.
價格行動：最後週三檢查，GSK股價在盤前交易中下跌4.69%，報36.38美元。
- Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
- Coya Therapeutics高劑量白細胞介素-2在中期阿爾茨海默病研究中未達到預期。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。
